and generalizability of pricing for the cancer services assessed when compared with other cancer treatments. Additionally, this study focused on services and transparency at NCI-CCs, which may limit comparisons to non-NCI centers. Most NCI-CCs are poorly compliant with the 2021 CMS price transparency rules, potentially stymieing efforts to limit proliferating cancer treatment costs and improve affordability for patients.

Fumiko Chino, MD
Jordan Johnson, BSRT, MSHA
Haley Moss, MD

Author Affiliations: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York (Chino); OncoSpark, Miami, Florida (Johnson); Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina (Moss).

Accepted for Publication: August 6, 2021.

Conflict of Interest Disclosures: Mr Johnson is employed by OncoSpark, an oncology value-based care and technology company. Dr Chino is funded in part through a National Institutes of Health/National Cancer Institute Cancer Center support grant (P30 CA008748). No other disclosures were reported.


CORRECTION

Error in Table 1: In the Original Investigation titled “Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma,” published online October 21, 2021, there was an error in Table 1. The highest listed Eastern Cooperative Oncology Group Performance Status should be “2-3” rather than “5.” This article has been corrected online.